Carl Zeiss Meditec launches new OCT applications for eye surgery
9 April 2009
Carl Zeiss Meditec has launched new optical coherence tomography (OCT) applications to support cataract, refractive, glaucoma and retina procedures.
The newest version of Cirrus HD-OCT 4.0 adds critical features to support cataract and refractive surgeons as well as advanced analyses for tracking change in glaucoma and managing retina disease. Cirrus 4.0 software has been released internationally and is pending FDA clearance in the US.
Cirrus HD-OCT 4.0 is aimed at practices that rely on advanced technologies to identify pre-existing eye diseases, to closely monitor disease progression and to determine the most appropriate course of treatment for each patient. The new software technologies can be seamlessly integrated onto any Cirrus HD-OCT platform.
“Since we first introduced OCT technology to the ophthalmic industry nearly fifteen years ago, we have continued to invest in applications that leverage clinical and scientific advances in the field as well as features that make the technology itself more efficient and user-friendly for practitioners,” said Michael Kaschke, President and Chief Executive Officer of Carl Zeiss Meditec.
"Cirrus is a valuable tool in my practice for both my cataract/ refractive surgery and glaucoma patients,” said Ike K Ahmed, MD, FRCSC, Assistant Professor at the University of Toronto and Clinical Assistant Professor at the University of Utah in Salt Lake City. “It helps me to identify potential problems in my pre-operative cataract/refractive workups and my patients more easily understand what they can expect post-operatively."
The Stratus OCT 6.0 upgrade includes the following enhancements:
These new features for Stratus OCT, combined with GPA software, provide more diagnostic functions than ever before. Version 6.0 is especially applicable to comprehensive ophthalmologists that require a consistent, cost-effective platform to identify and monitor cataract patients with pre-existing glaucoma or retina diseases.
Bookmark this page